Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Faron Pharmaceuticals Oy ( (GB:FARN) ) has provided an announcement.
Faron Pharmaceuticals Ltd announced the exercise of options by its CEO and CFO, resulting in the issuance of 111,000 new ordinary shares under the company’s 2015 Option Plan, generating gross proceeds of approximately EUR 120,990. This move is expected to impact the company’s equity structure, with the new shares set to be admitted to trading on Nasdaq First North Growth Market Finland and AIM, maintaining the total number of voting rights at 112,922,919.
More about Faron Pharmaceuticals Oy
Faron Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company based in Turku, Finland, focused on developing novel immunotherapies.
For detailed information about FARN stock, go to TipRanks’ Stock Analysis page.